Shares of Simcere Pharma (02096) rallied nearly 5% during Tuesday morning trading. As of the latest update, the stock was up 4.60%, trading at HK$12.73, with transaction volume reaching HK$45.33 million. The company is scheduled to hold its 2026 interim results presentation on August 21.

According to the company's positive profit alert announcement, Simcere Pharma expects first-half revenue to reach between RMB 4.55 billion and RMB 4.61 billion, representing a year-on-year increase of approximately 26.9% to 28.6%. Net profit attributable to shareholders is projected at RMB 810 million to RMB 860 million, up roughly 34.8% to 43.1% from the prior year. Adjusted net profit attributable to shareholders is anticipated to be in the range of RMB 950 million to RMB 1 billion, marking a year-on-year surge of approximately 46.5% to 54.2%. The robust performance is primarily attributed to increased revenue from innovative drugs and income generated from out-licensing agreements.

Huatai Securities noted that despite significant industry volatility in the second quarter, the company delivered results exceeding expectations, demonstrating strong market demand for its new product lineup and improved operational efficiency following management changes. Additionally, the normalization of business development activities is expected to drive sustained incremental growth. The brokerage projects that the company's full-year organic business will maintain the momentum indicated in its interim profit guidance, while profit margins could benefit further from continued business development initiatives. Huatai has maintained its "Buy" rating on the stock.